NL-OMON44758招募中3 期
A randomized double-blind placebo-controlled study to evaluate the efficacy and safety of Cinryze® (C1 esterase inhibitor [human]) for the treatment of acute antibody-mediated rejection in kidney transplant patients - SHP616-302
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- Shire
- 入组人数
- 7
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1.Be >= 18 and <=70 years of age.
- •2.Weigh >=45 kg with a body mass index (BMI) <35 kg/m2 at screening.
- •3.Have HLA DSA identified at the time of diagnosis of AMR. If it is anticipated that the local DSA results will not be available within the screening period, previously obtained local DSA results can be used to assess eligibility, if obtained after kidney transplant and within 30 days prior to the qualifying AMR episode. In any instance, a local DSA test should still be performed at the time of AMR diagnosis.
- •4.Have a first qualifying episode of AMR in the subject's current renal allograft between 72 hours and 12 months after transplant defined by a renal allograft biopsy demonstrating neutrophil and/or monocyte infiltration in the peritubular capillaries and/or glomeruli with or without evidence of C4d by immunohistopathology according to 2013 Banff criteria for AMR.
- •5.Have achieved adequate renal function defined as: Pre-AMR baseline eGFRMDRD >=20 mL/min/1.73m2 for a qualifying AMR episode occurring <=21 days after transplant or pre-AMR baseline eGFRMDRD >=30 mL/min/1.73m2 for a qualifying AMR episode occurring >21 days after
- •transplant. The pre-AMR baseline is the highest eGFRMDRD value obtained following the kidney transplant and within 30 days prior to the qualifying AMR episode. If more than one eGFRMDRD value is available, a mean of the 2 highest values (at least 1 day apart and both prior to the
- •AMR episode) will be used as the pre-AMR baseline value. If no eGFRMDRD was obtained within 30 days prior to biopsy, it can be evaluated within a 60 day period.
- •6.Receive first dose of investigational product at least 7 days after kidney transplant and within 7 days after the qualifying renal allograft biopsy procedure that was positive for AMR.
- •7.Be informed of the nature of the study and provide written informed consent before any study-specific procedures are performed.
- •8.If female and of child-bearing potential, have a negative urine pregnancy test confirmed by a negative serum beta human chorionic gonadotropin pregnancy test at the Screening Visit and must have a negative urine pregnancy test at the Day 1 visit.
- •9.Agree to comply with any applicable contraceptive requirements of the protocol.
排除标准
- •1.Have received pediatric en bloc kidney transplant.
- •2.Have primary Focal Segmental Glomerulosclerosis, rapidly progressive glomerulonephritis,membrano-proliferative glomerulonephritis type 1 (including C3 Glomerulopathy), dense deposit disease, or Thrombotic microangiopathy as the cause of native kidney failure.
- •3.Have prior or concurrent non-renal solid organ transplant or hematopoietic stem cell transplant (HSCT) or have more than 2 completed kidney transplant procedures (note: 1 double kidney transplant procedure is considered to be 1 procedure).
- •4.Have a known neoplastic lesion in the transplanted allograft.
- •5.Have, any ongoing infection that causes hemodynamic compromise or as determined by the investigator and/or medical monitor, any surgical or medical condition that could interfere with the administration of investigational product, interpretation of study results, or could compromise patient safety, including (as determined by the transplanting surgeon and documented in the operative report) any major technical complications of the renal artery, renal vein, or ureteral anastomosis.
- •6.Have ongoing treatment for hepatitits C virus (HCV) infection.
- •7.Have had a myocardial infarction (MI) within the past 6 months and/or at the time of screening are treated with anticoagulants and/or antiplatelet agents (excluding asprin) for a previous myocardial infarction.
- •8.Have a history of abnormal bleeding, clotting events or disorders (excluding a history of clotted hemodialysis access or superficial thrombophlebitis in the absence of medically-confirmed coagulopathy), any coagulopathy (docuemented or clinically suspected). For example, patients should be excluded if they have a history of renal allograft arterial or venous thrombosis, deep vein thrombosis, pulmonary embolism, ischemic cerebrovasculara accident (stroke) or transient ischemic attack (TIA), any large vessel thrmobosis..
- •9.Have a history of allergic reaction to CINRYZE or other blood products.
- •10.Have had any change in androgen therapy (eg, danazol, oxandrolone, stanozolol, testosterone), tranexamic acid, epsilon-aminocaproic acid, or other fibrinolytics within 3 months before the first dose of investigational product.
- •11.Have participated in the active dosing phase of any other investigational drug study within 30 days prior to dosing with investigational product.
- •12.Have any of the following local laboratory values reported prior to dosing with investigational product:
- •Within 24 hours prior to subject dosing, white blood cell count <0.5×10^9/L or >20×10^9/L (the value of >20 x 10^9/L should be excluded if obtained during steroid treatment)
- •Within 24 hours prior to dosing , platelet count <25×10^9/L or >600×10^9/L
- •13. Be pregnant or breastfeeding.
- •14. Have received any of the following agents within 1 month prior to the first dose of investigational product:
- •Sucrose-containing IVIg
- •Any C1 INH (plasma-derived [eg, CINRYZE®, Berinert®, Cetor®] or recombinant [eg, Rhucin®])
- •Eculizumab (Soliris®)
- •Ecallantide (Kalbitor®)
研究者
相似试验
已完成
2 期
Efficacy of Ashwagandha extract on generalized anxiety disorderCTRI/2022/04/042133Arjuna Natural Private Limited60
进行中（未招募）
1 期
ALASCCA-A randomized double-blind placebo-controlled study with ASAtreatment in colorectal cancer patients with mutations in the PI3Ksignaling pathway.Colon or rectal cancer tumor stage II-III, tumor with somatic alterationsin PIK3CA, PIK3R1 or PTEN.MedDRA version: 21.0Level: LLTClassification code 10010029Term: Colorectal cancer NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-004240-19-DKKarolinska University Hospital, Department of Molecular medicine and Surgery Karolinska Institutet, Gastrocentrum600
招募中
3 期
ALASCCA-A randomized double-blind placebo-controlled study with ASA treatment in colorectal cancer patients with mutations in the PI3K signaling pathway2024-513778-23-00Karolinska Institutet700
已完成
3 期
To determine whether Flexsure is safe, tolerable and effective in relieving symptoms of moderate osteoarthritis of the knee.CTRI/2011/07/001911Vital gNetics60
尚未招募
不适用
A randomized double-blind placebo-controlled study of Qingfei Jianpi desensitization prescription in early intervention of seasonal allergic rhinitisallergic rhinitisITMCTR2200006028Beijing Tongren Hospital ,Capital Medical University